Saurabh Suman, Verma Mahendra Kumar, Gautam Vaishali, Kumar Nitesh, Jain Vidhi, Goel Akhil Dhanesh, Gupta Manoj Kumar, Sharma Prem Prakash, Bhardwaj Pankaj, Singh Kuldeep, Nag Vijaya Lakshmi, Garg Mahendra Kumar, Misra Sanjeev
Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.
Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.
Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.
Understanding risk factors of symptomatic coronavirus disease 2019 (COVID-19) vis-à-vis asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, severe disease and death is important.
An unmatched case-control study was conducted through telephonic interviews among individuals who tested positive for SARS-CoV-2 in Jodhpur, India from 23 March to 20 July 2020. Contact history, comorbidities and tobacco and alcohol use were elicited using standard tools.
Among 911 SARS-CoV-2-infected individuals, 47.5% were symptomatic, 14.1% had severe COVID-19 and 41 (4.5%) died. Older age, working outside the home, cardiac and respiratory comorbidity and alcohol use were found to increase the risk of symptomatic disease as compared with asymptomatic infection. Current tobacco smoking (odds ratio [OR] 0.46 [95% confidence interval {CI} 0.26 to 0.78]) but not smokeless tobacco use (OR 0.81 [95% CI 0.55 to 1.19]) appeared to reduce the risk of symptomatic disease. Age ≥60 y and renal comorbidity were significantly associated with severe COVID-19. Age ≥60 y and respiratory and cardiac comorbidity were found to predispose to mortality.
The apparent reduced risk of symptomatic COVID-19 among tobacco smokers could be due to residual confounding owing to unknown factors, while acknowledging the limitation of recall bias. Cross-protection afforded by frequent upper respiratory tract infection among tobacco smokers could explain why a similar association was not found for smokeless tobacco use, thereby being more plausible than the 'nicotinic hypothesis'. Those with comorbidities and age ≥60 y should be prioritized for hospital admission.
了解2019冠状病毒病(COVID-19)症状性感染相对于无症状严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染、重症疾病和死亡的风险因素很重要。
通过电话访谈对2020年3月23日至7月20日在印度焦特布尔SARS-CoV-2检测呈阳性的个体进行了一项非匹配病例对照研究。使用标准工具获取接触史、合并症以及烟草和酒精使用情况。
在911名感染SARS-CoV-2的个体中,47.5%有症状,14.1%患有重症COVID-19,41人(4.5%)死亡。与无症状感染相比,年龄较大、外出工作、心脏和呼吸系统合并症以及饮酒会增加出现症状性疾病的风险。当前吸烟(比值比[OR]0.46[95%置信区间{CI}0.26至0.78])而非使用无烟烟草(OR 0.81[95%CI 0.55至1.19])似乎会降低出现症状性疾病的风险。年龄≥60岁和肾脏合并症与重症COVID-19显著相关。年龄≥60岁以及呼吸系统和心脏合并症易导致死亡。
吸烟者中COVID-19症状性感染风险明显降低可能是由于未知因素导致的残余混杂,同时承认存在回忆偏倚的局限性。吸烟者频繁的上呼吸道感染所提供的交叉保护可以解释为什么无烟烟草使用未发现类似关联,因此比“尼古丁假说”更具合理性。合并症患者和年龄≥60岁的患者应优先住院治疗。